<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764738</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4495s</org_study_id>
    <nct_id>NCT00764738</nct_id>
  </id_info>
  <brief_title>Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration</brief_title>
  <official_title>Study Investigating High Resolution OCT, Multifocal ERG and Microperimetry Outcomes of Monthly vs As Needed Ranibizumab in Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Macula Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retina Macula Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Visual outcomes using monthly ranibizumab therapy are well established in clinical trials,&#xD;
      but the best way to assess when and how to treat patients with PRN therapy has not been&#xD;
      proven. Information is lacking on Multi-focal ERG and microperimetry outcomes with&#xD;
      ranibizumab therapy. Additionally, VA and OCT outcomes don't always correlate and other&#xD;
      assessments such as the Multi-focal ERG and microperimetry may be useful as early predictors&#xD;
      of when patients should be retreated. This study will assess 2 groups (monthly and PRN&#xD;
      therapy) and assess high resolution OCT, microperimetry, and Multi-focal ERG outcomes. For&#xD;
      the PRN group retreatment will be based on OCT criteria. We will investigate if&#xD;
      microperimetry or multifocal ERG would have been an early predictor of fluid recurrence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multifocal Electroretinography N1-P1 Amplitude</measure>
    <time_frame>One Year</time_frame>
    <description>As measured within the central ring of the multifocal electroretinography study this measurement is the difference between the first positive peak (P1) and the first negative peak (N1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microperimetry Mean Sensitivity</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Foveal Thickness on Optical Coherence Tomography</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Neovascular Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Monthly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab injections every month for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>As Needed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab injections monthly for 4 months then as needed thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT, Multifocal ERG, Microperimetry</intervention_name>
    <description>OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.&#xD;
Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.&#xD;
Multifocal ERG done at the same monthly visits as the microperimetry.</description>
    <arm_group_label>As Needed</arm_group_label>
    <arm_group_label>Monthly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab Ophthalmic</intervention_name>
    <description>0.5 mg ranibizumab vs 2.0 mg ranibizumab</description>
    <arm_group_label>As Needed</arm_group_label>
    <arm_group_label>Monthly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study.&#xD;
&#xD;
          -  Age greater or equal to 50 years old.&#xD;
&#xD;
          -  Patients with active neovascular AMD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy (Positive pregnancy test) or lactation.&#xD;
&#xD;
          -  Premenopausal women not using adequate contraception. The following are considered&#xD;
             effective means of contraception: surgical sterilization or use of oral&#xD;
             contraceptives, barrier contraception with either a condom or diaphragm in conjunction&#xD;
             with spermicidal gel, an IUD, or contraceptive hormone implant or patch.&#xD;
&#xD;
          -  Any other condition that the investigator believes would pose a significant hazard to&#xD;
             the subject if the investigational therapy were initiated&#xD;
&#xD;
          -  Participation in another simultaneous medical investigation or trial&#xD;
&#xD;
          -  Concurrent eye disease in the study eye that could compromise visual acuity (e.g.,&#xD;
             diabetic retinopathy, advanced glaucoma)&#xD;
&#xD;
          -  Previous PDT therapy&#xD;
&#xD;
          -  Previous intravitreal steroid therapy within last 3 months&#xD;
&#xD;
          -  Previous anti-VEGF therapy in the past month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron P. Gallemore, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Macula Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Macula Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <results_first_submitted>August 16, 2020</results_first_submitted>
  <results_first_submitted_qc>August 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2020</results_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARMD</keyword>
  <keyword>AMD</keyword>
  <keyword>exudative AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Monthly Ranibizumab 0.5 mg</title>
          <description>Intravitreal ranibizumab 0.5 mg dosing monthly for entire study.</description>
        </group>
        <group group_id="P2">
          <title>PRN Ranibizumab 0.5 mg</title>
          <description>Intravitreal ranibizumab 0.5 mg dosing monthly for initial 4 injections followed by as needed dosing based on the presence of fluid on optical coherence tomography imaging.</description>
        </group>
        <group group_id="P3">
          <title>Monthly Ranibizumab 2.0 mg</title>
          <description>Intravitreal ranibizumab 2.0 mg dosing monthly for entire study.</description>
        </group>
        <group group_id="P4">
          <title>PRN Ranibizumab 2.0 mg</title>
          <description>Intravitreal ranibizumab 2.0 mg dosing monthly for initial 4 injections followed by as needed dosing based on the presence of fluid on optical coherence tomography imaging.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Monthly Ranibizumab 0.5 mg</title>
          <description>Intravitreal ranibizumab 0.5 mg dosing monthly for entire study.</description>
        </group>
        <group group_id="B2">
          <title>PRN Ranibizumab 0.5 mg</title>
          <description>Intravitreal ranibizumab 0.5 mg dosing monthly for initial 4 injections followed by as needed dosing based on the presence of fluid on optical coherence tomography imaging.</description>
        </group>
        <group group_id="B3">
          <title>Monthly Ranibizumab 2.0 mg</title>
          <description>Intravitreal ranibizumab 2.0 mg dosing monthly for entire study.</description>
        </group>
        <group group_id="B4">
          <title>PRN Ranibizumab 2.0 mg</title>
          <description>Intravitreal ranibizumab 2.0 mg dosing monthly for initial 4 injections followed by as needed dosing based on the presence of fluid on optical coherence tomography imaging.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.6" spread="1.0"/>
                    <measurement group_id="B2" value="75.8" spread="0.8"/>
                    <measurement group_id="B3" value="75.3" spread="1.4"/>
                    <measurement group_id="B4" value="78.8" spread="1.0"/>
                    <measurement group_id="B5" value="77.5" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Multifocal Electroretinography N1-P1 Amplitude</title>
        <description>As measured within the central ring of the multifocal electroretinography study this measurement is the difference between the first positive peak (P1) and the first negative peak (N1).</description>
        <time_frame>One Year</time_frame>
        <population>Required maintenance on device limited data collection for part of the study population.</population>
        <group_list>
          <group group_id="O1">
            <title>Monthly Ranibizumab</title>
            <description>Intravitreal ranibizumab injections monthly for entire study.</description>
          </group>
          <group group_id="O2">
            <title>PRN Ranibizumab</title>
            <description>Intravitreal ranibizumab injections monthly for initial 4 injections followed by as needed dosing based on the presence of fluid on optical coherence tomography imaging.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg</title>
            <description>Intravitreal ranibizumab 0.5 mg dosing</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg</title>
            <description>Intravitreal ranibizumab 2.0 mg dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Multifocal Electroretinography N1-P1 Amplitude</title>
          <description>As measured within the central ring of the multifocal electroretinography study this measurement is the difference between the first positive peak (P1) and the first negative peak (N1).</description>
          <population>Required maintenance on device limited data collection for part of the study population.</population>
          <units>nV/deg^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.4"/>
                    <measurement group_id="O2" value="5.3" spread="0.4"/>
                    <measurement group_id="O3" value="4.9" spread="0.4"/>
                    <measurement group_id="O4" value="4.0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.4"/>
                    <measurement group_id="O2" value="4.7" spread="0.4"/>
                    <measurement group_id="O3" value="4.4" spread="0.4"/>
                    <measurement group_id="O4" value="3.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Microperimetry Mean Sensitivity</title>
        <time_frame>One Year</time_frame>
        <population>For 4 patients, data was unavailable on microperimetry from all visits (including screening).</population>
        <group_list>
          <group group_id="O1">
            <title>Monthly Ranibizumab</title>
            <description>Intravitreal ranibizumab injections monthly for entire study.</description>
          </group>
          <group group_id="O2">
            <title>PRN Ranibizumab</title>
            <description>Intravitreal ranibizumab injections monthly for initial 4 injections followed by as needed dosing based on the presence of fluid on optical coherence tomography imaging.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg</title>
            <description>Intravitreal ranibizumab 0.5 mg dosing</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg</title>
            <description>Intravitreal ranibizumab 2.0 mg dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Microperimetry Mean Sensitivity</title>
          <population>For 4 patients, data was unavailable on microperimetry from all visits (including screening).</population>
          <units>dB</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="0.8"/>
                    <measurement group_id="O2" value="5.1" spread="0.7"/>
                    <measurement group_id="O3" value="5.7" spread="0.7"/>
                    <measurement group_id="O4" value="4.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="0.7"/>
                    <measurement group_id="O2" value="7.3" spread="0.8"/>
                    <measurement group_id="O3" value="7.3" spread="0.7"/>
                    <measurement group_id="O4" value="6.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Corrected Visual Acuity</title>
        <time_frame>One Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Monthly Ranibizumab</title>
            <description>Intravitreal ranibizumab injections monthly for entire study.</description>
          </group>
          <group group_id="O2">
            <title>PRN Ranibizumab</title>
            <description>Intravitreal ranibizumab injections monthly for initial 4 injections followed by as needed dosing based on the presence of fluid on optical coherence tomography imaging.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg</title>
            <description>Intravitreal ranibizumab 0.5 mg dosing</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg</title>
            <description>Intravitreal ranibizumab 2.0 mg dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity</title>
          <units>Letters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" spread="4.0"/>
                    <measurement group_id="O2" value="52.6" spread="3.3"/>
                    <measurement group_id="O3" value="48.6" spread="3.5"/>
                    <measurement group_id="O4" value="54.5" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="3.8"/>
                    <measurement group_id="O2" value="58.6" spread="3.4"/>
                    <measurement group_id="O3" value="55.4" spread="3.4"/>
                    <measurement group_id="O4" value="61.1" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Foveal Thickness on Optical Coherence Tomography</title>
        <time_frame>One Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Monthly Ranibizumab</title>
            <description>Intravitreal ranibizumab injections monthly for entire study.</description>
          </group>
          <group group_id="O2">
            <title>PRN Ranibizumab</title>
            <description>Intravitreal ranibizumab injections monthly for initial 4 injections followed by as needed dosing based on the presence of fluid on optical coherence tomography imaging.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg</title>
            <description>Intravitreal ranibizumab 0.5 mg dosing</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab 2.0 mg</title>
            <description>Intravitreal ranibizumab 2.0 mg dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Central Foveal Thickness on Optical Coherence Tomography</title>
          <units>micrometers</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341.2" spread="21.9"/>
                    <measurement group_id="O2" value="298.1" spread="16.8"/>
                    <measurement group_id="O3" value="308.2" spread="14.9"/>
                    <measurement group_id="O4" value="331.1" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.8" spread="17.0"/>
                    <measurement group_id="O2" value="227.9" spread="12.2"/>
                    <measurement group_id="O3" value="231.7" spread="14.3"/>
                    <measurement group_id="O4" value="242.7" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Monthly Ranibizumab 0.5 mg</title>
          <description>Intravitreal ranibizumab 0.5 mg dosing monthly for entire study.</description>
        </group>
        <group group_id="E2">
          <title>PRN Ranibizumab 0.5 mg</title>
          <description>Intravitreal ranibizumab 0.5 mg dosing monthly for initial 4 injections followed by as needed dosing based on the presence of fluid on optical coherence tomography imaging.</description>
        </group>
        <group group_id="E3">
          <title>Monthly Ranibizumab 2.0 mg</title>
          <description>Intravitreal ranibizumab 2.0 mg dosing monthly for entire study.</description>
        </group>
        <group group_id="E4">
          <title>PRN Ranibizumab 2.0 mg</title>
          <description>Intravitreal ranibizumab 2.0 mg dosing monthly for initial 4 injections followed by as needed dosing based on the presence of fluid on optical coherence tomography imaging.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitic Glaucoma</sub_title>
                <counts group_id="E1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vitreous Hemorrhage</sub_title>
                <counts group_id="E1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal Abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Injection Site Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ron Gallemore</name_or_title>
      <organization>Retina Macula Institute</organization>
      <email>rongallemoremd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

